Statins: Immunomodulators for autoimmune rheumatic disease?

Lupus

Volumn 14, Issue 3, 2005, Pages 192-196

  Jury, Elizabeth C ^a   Ehrenstein, M R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Rheumatoid arthritis; Statins; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; ATORVASTATIN; C REACTIVE PROTEIN; CASPASE 3; CASPASE 9; CHOLESTEROL; FLUINDOSTATIN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVINOLIN; PLACEBO; PROTEIN BCL 2; RANTES; SELECTIN; SIMVASTATIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; APOPTOSIS; ARTHRITIS; ATHEROGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COLLAGEN INDUCED ARTHRITIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ERYTHROCYTE SEDIMENTATION RATE; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA CELL; LIPID RAFT; MEMORY CELL; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATIC DISEASES;

EID: 15944384675     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu2135oa     Document Type: Conference Paper

References (72)

1. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-223.
2. Tsunekawa T, Hayashi T, Kano H et al. Cerivastatin, a hydroxymethyl-glutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-379.
3. Buchwald H, Campos CT, Boen JR et al. for the POSCH group. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol 1995; 26: 351-357.
4. Baetta R, Camera M, Comparato C et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2002; 22: 692.
5. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
6. Wenke K, Meiser B, Thiery J et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96: 1398-1402.
7. Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors. Stalins as anti-inflammatory agents? Circulation 2004; 109 (Suppl. II): II-18-II-26.
8. Halcox JPJ, Deanfield JE. Beyond the laboratory. Clinical implications for statin pleiotropy. Circulation 2004; 109 (Suppl. II): II-42-II-48.
9. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004; 172: 2903-2908.
10. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol 2003; 23: 1055-1069.
11. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
12. Bessant R, Hingorani A, Patel L et al. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology 2004; 43: 924-929.
13. Ehrenstein MR, Jury E, Mauri C. Statins for atherosclerosis: as good as it gets? New Engl J Med 2005; 352: 73-75.
14. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399.
15. Sadeghi MM, Tiglio A, Sadigh K et al. Inhibition of interferon-gamma- mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 2001; 71: 1262-1268.
16. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001; 131: 41-46.
17. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003; 14: 1336-1348.
18. Abusamieh M, Ash J. Atherosclerosis and systemic lupus erythematosus. Cardiol Rev 2004; 12: 267-275.
19. Turesson C. Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Des 2004; 10: 129-143.
20. Aktas O, Waiczies S, Smorodchenko A et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725-733.
21. Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
22. Leung BP, Sattar N, Crilly A et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-1530.
23. Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators. Comparison with interferon-β1b in MS. Neurology 2002; 59: 990-997.
24. Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-1608.
25. Abud-mendoza C, de la Fuente H, Cuevas-Orta E et al. Therapy with statins in patients with refactory rheumatic diseases: a preliminary study. Lupus 2003; 12: 607-611.
26. McCarey DW, McInnes IB, Madhok R et al. Trail of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 2015-2021.
27. Nissen SE, Tucu EM, Schoenhagen P et al. Effect of statin therapy on LDL-cholesterol, C-reactive protein, and the progression of coronary artery disease. New Engl J Med 2005; 352: 29-38.
28. Ridker PM, Cannon CP, Morrow D et al. Clinical relevance of achieved C-reactive protein levels following treatment with statin therapy. New Engl J Med 2005; 352: 20-28.
29. Jevnikar AM, Grusby MJ, Glimcher LH. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J Exp Med 1994; 179: 1137.
30. Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZB × NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987; 166: 798.
31. Hasegawa K, Hayashi T, Maeda K. Promotion of lupus in NZB × NZWF1 mice by plasmids encoding interferon (IFN)-gamma but not by those encoding interleukin (IL)-4. J Comp Pathol 2002; 127: 1.
32. Yokoyama H, Takabatake T, Takaeda M et al. Up-regulated MHC-class II expression and gamma-IFN and soluble IL-2R in lupus nephritis. Kidney Int 1992; 42: 755.
33. Lockshin MD, Salmon JE, Roman MJ. Atherosclerosis and lupus: a work in progress. Arthritis Rheum 2001; 44: 2215.
34. Hakamada-Taguchi R, Uehara Y, Kuribayashi K et al. Inhibition of hydroxymethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93: 948-956.
35. Hanson J, Bossingham D. Lupus-like syndrome associated with simvastatin. Lancet 1998; 352: 1070.
36. Jimenez-Alonso J, Jaimez L, Sabio JM, Hidalgo C, Leon L. Atorvastatin-induced reversible positive antinuclear antibodies. Am J Med 2002; 112: 329.
37. Srivastana M, Rencic A, Diglio G et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139: 45-49.
38. Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol 2004; 22: 157-166.
39. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastarin inhibits autoreactive B cell activation and delays lupus development in NZB/WF1 mice. J Immunol 2004; 173: 7641-7646.
40. Fellstrom B, Holdaas H, Jardine AG et al. Assessment of Lescol in Renal Transplantation Study Investigators. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004; 66: 1549-1555.
41. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(23 Suppl. 1): III50-III57.
42. Renders L, Mayer-Kadner I, Koch C et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 2001; 16: 141-146.
43. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999; 33: 1176-1179.
44. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastarin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587.
45. Schonbeck U, Gerdes N, Varo N et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106: 2888-2893.
46. Semb AG, van Wissen S, Ueland T et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 2003; 41: 275-279.
47. Nishibori M, Takahashi HK, Mori S. The regulation of ICAM-1 and LFA-1 interaction by autacoids and starins: a novel strategy for controlling inflammation and immune responses. J Pharmacol Sci 2003; 92:7-12.
48. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Stalins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692.
49. Chung HK, Lee IK, Kang H et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002; 34: 451-461.
50. Rasmussen LM, Hansen PR, Nabipour MT et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 2001; 360: 363-370.
51. Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 2003; 338: 17-24.
52. Kaneider NC, Reinisch CM, Dunzendorfer S et al. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 2001; 158: 23-33.
53. Kato T, Hashikabe H, Iwata C, Akimoto K, Hattori Y. Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells. Biochim Biophys Acta 2004; 1689: 267-272.
54. Buemi M, Allegra A, Senatore M et al. Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol 1999; 370: 201-203.
55. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003; 31: 779-783.
56. Focking M, Besselmann M, Trapp T. Statins potentiate caspase-3 activity in immortalized murine neurons. Neurosci Lett 2004; 355: 41-44.
57. Kabouridis PS, Janzen J, Magee AL, Ley SC. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signalling pathways in T lymphocytes. Eur J Immunol 2000; 30: 954-963.
58. Yokoyama K, Ishibashi T, Ohkawara H et al. HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. Circulation 2002; 105: 962-967.
59. Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood 1996; 88: 4611-4619.
60. Dichtl W, Dulak J, Frick M et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58-63.
61. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110: 285-288.
62. Hillyard DZ, Jardine AG, McDonald KJ, Cameron AJ. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. Atherosclerosis 2004; 172: 219-228.
63. Silvius JR. Role of cholesterol in lipid raft formation: lessons from lipid model systems. Biochim Biophys Acta 2003; 1610: 174-183.
64. Janes PW, Ley SC, Magee AI, Kabouridis PS. The role of lipid rafts in T cell antigen receptor (TCR) signalling. Sem Immunol 2000; 12: 23-34.
65. Razzaq TM, Ozegbe P, Jury EC et al. Regulation of T-cell receptor signalling by membrane microdomains. Immunology 2004; 113: 413-426.
66. Xavier R, Brennan T, Li Q, McCormack C, Seed B. Membrane compartmentation is required for efficient T cell activation. Immunity 1998; 8: 723-732.
67. Silvius JR. Mechanisms of Ras protein targeting in mammalian cells. J Membr Biol 2002; 190: 83-92.
68. Jury EC, Kabouridis PS, Abba A, Mageed RA, Isenberg DA. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1343-1354.
69. Jury EC, Kabouridis PS, Flores-Borja F, Mageed RA, Isenberg DA. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 2004; 113: 1176-1187.
70. Krishnan S, Nambiar MP, Warke VG et al. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 2004; 172: 7821-7831.
71. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002; 110: 597-603.
72. Gringhuis SI, Leow A, Papendrecht-van der Voort EAM et al. Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid lymphocytes in rheumatoid arthritis. J Immunol 2000; 164: 2170-2179.